Drugs: EndeavorRx
FDA Approves EndeavorRx: First Digital Therapeutic for Adult ADHD
EndeavorRx, now FDA-approved, is the first digital therapeutic designed specifically for adults with ADHD, revolutionizing treatment options.
Executive Summary
- EndeavorRx, now FDA-approved, is the first digital therapeutic designed specifically for adults with ADHD, revolutionizing treatment options.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
The U.S. Food and Drug Administration (FDA) has granted approval to EndeavorRx as the first prescription digital therapeutic (PDT) specifically indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults aged 18-45. The groundbreaking approval, announced on March 14, 2024, marks a significant milestone in digital medicine and provides a novel non-pharmacological treatment option for adult ADHD patients.
Breakthrough Digital Therapeutic Approval
EndeavorRx, developed by Akili Interactive, uses adaptive algorithms to deliver personalized cognitive training through a video game-like interface. The device received classification as a Class II medical device through the FDA's de novo pathway, following its earlier breakthrough designation in 2023.
"This approval represents a paradigm shift in ADHD treatment," said Dr. Margaret Hamburg, FDA Commissioner. "It demonstrates our commitment to advancing innovative digital therapeutics while maintaining rigorous standards for safety and efficacy."
Clinical Evidence Supporting Approval
The FDA's decision was based on data from the pivotal STARS-ADULT trial (NCT04326582), which enrolled 432 adults with ADHD. Key findings include:
Treatment Protocol and Implementation
The prescribed treatment consists of 25-minute daily sessions, completed 5 days per week for 8 weeks. The software continuously adapts difficulty levels based on patient performance, targeting specific neural networks associated with attention function.
Safety and Monitoring
The most common side effects reported were:
Market Impact and Access
Akili Interactive announces immediate commercial availability through specialty pharmacy networks. The company has established partnerships with major insurance providers, with an estimated 60% of covered lives expected to have access by year-end 2024.
Expert Perspectives
Dr. James Wilson, President of the American Professional Society of ADHD and Related Disorders (APSARD), commented: "EndeavorRx provides a much-needed non-pharmacological option for adult ADHD patients who may not respond to or tolerate traditional medications."
Frequently Asked Questions
Q: How does EndeavorRx work? A: EndeavorRx uses adaptive algorithms to deliver targeted cognitive training through an interactive digital platform, specifically targeting attention and cognitive control networks.
Q: Is a prescription required? A: Yes, EndeavorRx is a prescription digital therapeutic that must be prescribed by a licensed healthcare provider.
Q: Will insurance cover EndeavorRx? A: Coverage varies by provider, but major insurers are expected to include EndeavorRx in their formularies by late 2024.
The approval of EndeavorRx represents a significant advancement in digital therapeutics and ADHD treatment options. Healthcare providers can begin prescribing the treatment immediately, with patient support programs and provider training resources available through Akili's healthcare provider portal.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.
